Emadine (emedastine) is filed as Ophthalmic Antihistamine. The sections below restate public label fields stored for this profile.
INDICATIONS AND USAGE EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% is indicated for the temporary relief of the signs and symptoms of allergic conjunctivitis.
CLINICAL PHARMACOLOGY Emedastine is a relatively selective, histamine H1 antagonist. In vitro examinations of emedastine's affinity for histamine receptors (H1: Ki = 1.3 nM, H2: Ki = 49,067 nM, and H3: Ki = 12,430 nM) demonstrate relative selectivity for the H1-histamine receptor. In vivo studies have shown concentration-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration. Emedastine appears to be devoid of effects on adrenergic, dopaminergic and serotonin receptors. Following topical administration in man, emedastine was shown to have low systemic exposure. In a study involving 10 normal volunteers dosed bilaterally twice daily for 15 days with emedastine ophthalmic solution 0.05%, plasma concentrations of the parent compound were generally below the quantitation limit of the assay (less than 0.3 ng/mL). Samples in which emedastine was quantifiable, ranged from 0.30 to 0.49 ng/mL. The elimination half-life of oral emedastine in plasma is 3-4 hours. Approximately 44% of the oral dose is recovered in the urine over 24 hours with only 3.6% of the dose excreted as parent drug. Two primary metabolites, 5- and 6-hydroxyemedastine, are excreted in the urine as both free and conjugated forms. The 5’-oxoanalogs of 5- and 6-hydroxyemedastine and the N-oxide are also formed as minor metabolites. In an environmental study, patients with allergic conjunctivitis were treated with EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% for six weeks. The results demonstrated that EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% provides relief of the signs and symptoms of allergic conjunctivitis. In conjunctival antigen challenge studies, in which subjects were challenged with antigen both initially and up to four hours after dosing, EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% was demonstrated to be significantly more effective than placebo in preventing ocular itching associated with allergic conjunctivitis.
WARNINGS FOR TOPICAL OPHTHALMIC USE ONLY - NOT FOR INJECTION OR ORAL USE.
CONTRAINDICATIONS EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% is contraindicated in persons with a known hypersensitivity to emedastine difumarate or any of its components.
ADVERSE REACTIONS In controlled clinical studies of EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% lasting for 42 days, the most frequent adverse reaction was headache 11%. The following adverse experiences were reported in less than 5% of patients: Abnormal dreams, asthenia, bad taste, blurred vision, burning or stinging, corneal infiltrates, corneal staining, dermatitis, discomfort, dry eye, foreign body sensation, hyperemia, keratitis, pruritus, rhinitis, sinusitis and tearing. Some of these events were similar to the underlying disease being studied.
DOSAGE AND ADMINISTRATION The recommended dose is one drop in the affected eye up to four times daily.
According to its FDA label, Emadine (emedastine) is approved for: INDICATIONS AND USAGE EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% is indicated for the temporary relief of the signs and symptoms of allergic conjunctivitis. For medical advice, please talk to your prescriber or pharmacist.
Emadine (emedastine) belongs to the Ophthalmic Antihistamine class of medications.
The FDA label lists Emadine (emedastine) as: HOW SUPPLIED EMADINE ® (emedastine difumarate ophthalmic solution) 0.05% is supplied as follows: 5 mL in opaque, plastic DROP-TAINER ® dispenser. 5 mL: NDC 0065-0325-05 STORAGE : Store at 4°C to 30°C (39°F-86°F). Rx Only ©2002, 2003, 2009, 2018 Novartis Distributed by: ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Alcon ® a Novartis company Revised: April 2018 T2018-34. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Emadine (emedastine) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Emadine (emedastine) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Emadine (emedastine) in our latest ingest. Recall data can change daily — verify at FDA.gov.
Loading full data from Know Your Drugs Institute…